Vidutolimod/Nivolumab Under Evaluation in PD-1-Refractory Advanced Melanoma
Source: OncLive, May 2021
The safety and efficacy of the combination of vidutolimod (CMP-001) and nivolumab (Opdivo) is currently under investigation in patients with PD-1–refractory advanced melanoma, as part of the ongoing phase 2 CMP-001-010 trial (NCT04698187).1
